Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to $999000.0.

  • Serina Therapeutics' Share-based Compensation fell 885.04% to $999000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 13851.9%. This contributed to the annual value of $2.6 million for FY2024, which is 1028000.0% up from last year.
  • Per Serina Therapeutics' latest filing, its Share-based Compensation stood at $999000.0 for Q3 2025, which was down 885.04% from $890000.0 recorded in Q2 2025.
  • In the past 5 years, Serina Therapeutics' Share-based Compensation ranged from a high of $1.1 million in Q3 2024 and a low of $2000.0 during Q1 2023
  • In the last 5 years, Serina Therapeutics' Share-based Compensation had a median value of $251000.0 in 2021 and averaged $403500.0.
  • Its Share-based Compensation has fluctuated over the past 5 years, first crashed by 9916.32% in 2023, then surged by 264000.0% in 2024.
  • Quarter analysis of 5 years shows Serina Therapeutics' Share-based Compensation stood at $263000.0 in 2021, then crashed by 56.65% to $114000.0 in 2022, then plummeted by 64.91% to $40000.0 in 2023, then skyrocketed by 2370.0% to $988000.0 in 2024, then increased by 1.11% to $999000.0 in 2025.
  • Its Share-based Compensation stands at $999000.0 for Q3 2025, versus $890000.0 for Q2 2025 and $956000.0 for Q1 2025.